



UKKW
VIRTUAL

REGISTER NOW

A series of educational sessions will be held over a two week period

PROGRAMME OVERVIEW

Monday 5th October

- ~ COVID-19 associated Acute Kidney Injury
- ~ Dialysis update – from COVID and into the future

Tuesday 6th October

- ~ Best clinical abstracts
- ~ New world of clinical trials how do we make it work

Wednesday 7th October

- ~ Improving Diabetes Care in Haemodialysis - Yes we can
- ~ Chronic kidney disease: redefining care

Thursday 8th October

- ~ Single cell 'omics' in renal disease research
- ~ Best Science abstracts

Friday 9th October

- ~ It's Friday, 5pm and the phone goes

Tuesday 13th October

- ~ Right Time, Right Place, Right Role

Wednesday 14th October

- ~ UK Renal Registry – audit and research
- ~ Pathogenesis and treatment of glomerular disease and vasculitis

Thursday 15th October

- ~ Coping with Covid: Rising to the Challenge, Learning for the future.

Please see the programme details on page 3-8 for timings of the live educational sessions. As attendees view the live sessions, the platform will provide the opportunity for everyone to submit comments, feedback and questions directly to the presenters via live Q&A and discussion forums.

On behalf of both the Renal Association and the British Renal Society, we have great pleasure inviting you to attend UKKW Virtual 2020.

INTRODUCTION

In response to the global challenge, posed by the COVID-19 pandemic, UKKW will deliver a series of educational sessions using a virtual platform held over a two week period, starting on Monday 5th October, through to Thursday 15th October. The renal community has been at the forefront of the pandemic, and these events will also capture the experience and learnings during this time.



There will also be a virtual exhibition with the opportunity to meet industry representatives to discuss some of the latest devices and treatment options available, along with a poster hall.

We look forward to seeing you in October for an interesting and enjoyable conference.

REGISTRATION

UKKW would like to ensure this event is available for the whole renal team. We are also pleased to announce that Renal Departments can register all team members for just £100.

Additionally, individual registrations are available:

- Individual registration - £25
- Student - £15
- Patient - FoC
- Industry - £250

To register, please click [HERE](#).

UKKW VIRTUAL

UKKW Virtual is a great opportunity to virtually meet and network with colleagues who share your enthusiasm for best practice in kidney care and renal science. The platform will open from 1200 hours on 5th October and close at 1900 hours on 15th October.

MEETING HUB

The virtual platform allows you to network with other attendees. By simply scrolling through attendees or using the advance search, you can see all attendees whom you can chat with or arrange instant face to face meetings at any time during the day.

POSTER GALLERY

In the poster hall is open to visit from 5th-15th October and will allow you to review abstracts, download posters and view any presentations that have been uploaded. You can also submit your questions directly to the author via the Q&A box.

SUPPORT

In order to log into the event platform we recommend that delegates use Google Chrome. Other browsers, such as Microsoft Edge, Firefox and Safari are also supported. Please ensure that you install a compliant browser prior to logging in. In addition, at any time during the conference support is available by clicking on the red live support icon at the top right hand side of the screen.

VIRTUAL RUN

UKKW are organising a virtual run. Take part on an individual basis, or enter a team to complete 26.2 miles during the time of the virtual conference. Further details are to follow.

SOCIAL MEDIA

Please use the following on social media #UKKW2020.

PROGRAMME

Monday 5th October

1555-1628 Sponsored sessions

1555-1610
Vifor Pharma
Sponsored Session –
High-dose proactive
intravenous iron treatment
in ESKD – sub-analysis
from the PIVOTAL study –
Professor Phil Kalra

1613-1628
Presidents' Welcome

16.30-17.30 Session 1

COVID-19 associated Acute Kidney Injury
Chairs: *Nick Selby and John Prowle*

Introduction and overview of AKI in
COVID-19 – *Professor Nick Selby*

Causes of AKI in COVID-19 – is this a
different disease? – *Dr Chris Laing*

Challenges and solutions when performing
RRT in COVID-19 – *Dr Marlies Ostermann*

Adapting an acute dialysis service for a
pandemic situation – *Dr Smeeta Sinha*

What are the long-term consequences of AKI
in COVID-19? – *Dr Kate Bramham*

Interactive Q&A – all speakers

17.30-17.45

Exhibition,
posters,
networking,
comfort break

17.45-18.45 Session 2

Dialysis update – from COVID and into
the future
Chairs: *Karen Jenkins and Sandip Mitra*

Introduction – *Karen Jenkins*

Planning in-centre haemodialysis services
during COVID-19 pandemic – successes and
lessons learnt – *Clara Day*

Epidemiology of COVID-19 across RRT
modalities (differences between infection
rates and outcomes) – *Manuela Savino*

Practical strategies to increase the
utilisation of home therapies –
Elaine Bowes

Home haemodialysis – patients' perspectives

- HHD during the COVID pandemic –
Nick Palmer
- HHD from before (and after) COVID –
Maddy Warren

Q&A and roundtable discussion

18.45-19.30

Exhibition,
posters and
networking

Tuesday 6th October

1613-1628 Sponsored session

Alexion Sponsored
Session – Evolving
Treatment Considerations
for Patients with
Atypical- HUS
Chair: *Professor Neil Sheerin*

16.30-17.30 Session 1

Best clinical abstracts
Chairs: *Sally Johnson and Aisling McMahon*

- 62 - Stable calcium isotopes: a novel
biomarker of bone mineralisation in

17.30-17.45

Exhibition,
posters,
networking,
comfort break

17.45-18.45 Session 2

Clinical Trials – Generating Evidence to
Advance Care
Chairs: *Thomas Hiemstra and Rona Smith*

The RECOVERY Trial – *Professor Richard
Haynes*

18.45-19.30

Exhibition,
posters and
networking

PROGRAMME continued

Overview and mechanism of action of Ravulizumab, a long-acting complement C5 inhibitor –
Professor Neil Sheerin

Key efficacy and safety aspects of the Phase 3 clinical trial in adult patients with aHUS –
Dr Paramit Chowdhury

Q&A

children with chronic kidney disease –
Dr Rukshana Shroff

- 163 - A randomized, controlled trial of rituximab versus azathioprine after induction of remission with rituximab for patients with ANCA-associated vasculitis and relapsing disease – *Dr Rona Smith*
- 584 - The PrEscription of intraDialytic exercise to improve quALity of Life (PEDAL) in patients with chronic kidney disease trial: A multi-centre randomised controlled trial – *Dr Sharlene Greenwood*
- 9 - Kidney transplant outcomes for children and young adults in the UK –
Dr Alexander Hamilton
- 396 - Major Adverse Cardiovascular Events (MACE) after kidney transplantation: a population-cohort analysis of English transplant centres – *Dr Benjamin Anderson*
- 149 - Associations with peritoneal dialysis treatment failure for children and young adults in the UK – *Dr Alexander Hamilton*

Top Line results from the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD study) – *Professor David Wheeler on behalf of the DAPA-CKD Trials Committees and Investigators*

Results from the Paclitaxel-coated balloons and angioplasty of arteriovenous fistulas (PAVE) trial – *Dr Mike Robson*

Wednesday 7th October

1555-1628
Sponsored sessions

1555-1610
Napp Sponsored Session – CREDENCE & SGLT2i's usage in Diabetic Kidney Disease (DKD) How, when, where and why? –
Professor Claire Sharpe

16.30-17.30
Session 1

Improving Diabetes Care in Haemodialysis – Yes we can
Chairs: *Apexa Kuverji and Jo Reed*
Chairs Introduction
DiH why, what and how – *Dr James Burton*

17.30-17.45

Exhibition, posters, networking, comfort break

17.45-18.45
Session 2

Chronic kidney disease: redefining care Chairs: *Paul Cockwell and Mark Jesky*
SGLT-2 inhibitors – the current status: *Professor Maarten Taal*

18.45-19.30

Exhibition, posters and networking

PROGRAMME continued

1613-1628
Vifor Pharma
Sponsored Session –
 CKD – Is it time to rethink
 medicines optimisation? –
Dr Leonard Ebah

How the Dietitian can improve the diabetes
 care for people with diabetes on HDx – *TBC*

Monitoring glycaemia for people with
 diabetes on haemodialysis – pitfalls and
 solutions – *Dr Tahseen Chowdhury*

Q&A – 10 minutes

The role of the pharmacist in the primary and
 secondary care management of CKD –
Clare Morlidge

Virtual CKD clinics; Covid and beyond –
Gavin Dreyer

Can electronic patient reported outcomes
 define patient initiated follow-up – *Sabine*
van der Veer

Thursday 8th October

1613-1628
Sponsored session

16.30-17.30
Session 1

17.30-17.45

17.45-18.45
Session 2

18.45-19.30

Vifor Pharma
Sponsored Session –
 Acute hyperkalaemia –
 integrating potassium
 binders into our clinical
 practice –
Dr Will Hinchliffe

Single cell 'omics' in renal disease
 research
 Chairs: *Gavin Welsh*

Human Kidney Cell Atlas - Applications for
 nephrology and transplantation –
Professor Menna Clatworthy

Podocyte 'omics' identifies novel signalling
 pathways in albuminuria kidney disease –
Professor Richard Coward

- 128 - Single nucleus RNA sequencing identifies new classes of renal proximal tubular epithelial cell in a chronic renal fibrosis model – *Yeuh-An Lu*
- 402 - Kidney single-cell atlas reveals myeloid heterogeneity in progression and regression of kidney disease – *Eoin O'Sullivan*
- 409 - Renal epithelial senescence drives post injury fibrosis – *Eoin O'Sullivan*

Exhibition,
 posters,
 networking,
 comfort break

Best Science abstracts
 Chairs: *Gavin Welsh*

- 280 - Sirt5 deletion protects from ischaemic AKI and enhances nephrotoxic CKD – *Timo Hascheler*
- 360 - Endothelial glycocalyx heparan sulphate plays a key role in glomerular barrier function in health and is amenable to therapeutic targeting in diabetes – *Dr Monica Gamez*
- 370 - Dapagliflozin inhibition of non-canonical Smad signalling prevents fibrotic outcomes in diabetic kidney disease – *Xinlu Pan*
- 390 - Glomerular microRNAs are primary instigators of Diabetic Nephropathy – *Dr Alexa Wonnacott*
- 463 - Mineralocorticoid receptor blockade preserves the glomerular endothelial glycocalyx and normalises glomerular permeability in diabetic nephropathy – *Dr Michael Crompton*

Exhibition,
 posters and
 networking

PROGRAMME continued

- 418 - Single cell RNA sequencing of immune cells in models of acute kidney injury and chronic renal fibrosis – *Dr Bnar Talabani*

- 483 - Identification of differentially methylated genes in individuals with end-stage kidney disease attributed to diabetic kidney disease – *Dr Laura Smyth*

Friday 9th October

16.30-18.00

Its Friday, 5pm and the phone goes
Chair: *Lynne Sykes and Marie Condon*

Antibody Mediated Rejection – *Michelle Willicombe*

Hepatorenal syndrome – *Professor Andrew Davenport*

Cardiorenal syndrome - *Professor Phil Kalra*

16.00-16.45

Exhibition,
posters and
networking

Tuesday 13th October

1613-1628
Sponsored session

16.30-18.30

Quanta Sponsored
Workshop –
Quanta Dialysis
Technologies: Living with
Dialysis Interview

Limited to 40 delegates

Right Time, Right Place, Right Role
Chair: *Ellen Castle and Helen Hurst*

PART ONE: The 2020 Work Force Planning Document Launch
Chairs welcome and intro

- Where we started and where we are now; work force planning – *Hannah Young*
- Key learnings from the whole MDT
- Commissioning update – *Sandip Mitra and Ian Wren*
- GIRFT -Why the work force matters – *Dr Graham Lipkin*
- Q and A panel with all speakers

PART TWO: Changes in workforce during COVID

- Changes to the medic work force – *Sunil Bandari*
- Changes to the ART workforce – *Roger Moore*
- and d) Changes to the therapy workforce – *Juliet Mayes and Dr Sharlene Greenwood*
- The leadership conundrum in COVID – *Steve Andrews*
- Working towards the future – *Karen Jenkins*
- Q and A with all speakers

Exhibition,
posters and
networking

PROGRAMME continued

Wednesday 14th October

1613-1628 Sponsored session	16.30-17.30 Session 1	17.30-17.45	17.45-18.45 Session 2	18.45-19.30
<p>Sanofi Sponsored Session – Fabry disease and the impact of proactive renal medicine <i>Professor John A Sayer</i> <i>Dr Eve Miller-Hodges</i></p>	<p>UK Renal Registry – audit and research Chairs: <i>Ron Cullen</i> and <i>Fran Benoy-Deeney</i></p> <p>Chairs welcome to the session</p> <p>Introduction & overview – <i>Dr Retha Steenkamp</i>, <i>Professor James Medcalf</i> and <i>Professor Dorothea Nitsch</i></p> <p>Epidemiology of COVID-19 across RRT modalities – <i>Dr Manuela Savino</i></p> <p>AKI in a national cohort of children: epidemiology and outcomes using linked electronic health data – <i>Dr Lucy Plumb</i></p> <p>Patient transitions between KRT, CKD and AKI datasets at the UK Renal Registry – <i>Dr Barnaby Hole</i></p> <p>Working with the UK Renal Registry – <i>Dr Katharine Evans</i> and <i>Tom Gray</i></p> <p>Q&A session</p>	<p>Exhibition, posters, networking, comfort break</p>	<p>Pathogenesis and treatment of glomerular disease and vasculitis Chair: <i>Sally Hamour</i></p> <ul style="list-style-type: none"> • 544 - Peripheral T helper cells may play a significant role in the pathogenesis of ANCA associated vasculitis – <i>Dr Seerapani</i> • 292 - Neutrophils are required for anti-myeloperoxidase antibody vasculitis but inhibition of myeloperoxidase does not affect disease – <i>Dr Fernanda Florez-barros</i> • 59 - The safety profile of repeat rituximab treatment in ANCA-associated vasculitis – a 10 year single centre study – <i>Dr Pek Ghe Tan</i> • 567 - Long term maintenance rituximab for ANCA-associated vasculitis: infection and relapse prediction models – <i>Dr Mark McClure</i> • 415 - Treatment of adult patients with relapsing Minimal Change Disease with targeted B cell depletion – <i>Dr Rakesh Dattani</i> • 428 - Contactin-1 is a novel antigen in primary membranous glomerulonephritis (MGN) and in CIDP-associated MGN – <i>Professor Alan Salama</i> • 374 - Five and Ten Year Outcomes of a Large Cohort of Patients with Membranous Nephropathy treated with Tacrolimus – <i>Lina Nikolopoulou</i> • 259 - Strategies for Reduction of Cardiovascular Risk: Effect of Time and Different Treatments on Lipids in Membranous Nephropathy – <i>Dr Thomas Oates</i> 	<p>Exhibition, posters and networking</p>

PROGRAMME continued

Thursday 15th October

16.30-18.30

Coping with Covid: Rising to the Challenge, Learning for the future.

Chairs: *Fiona Loud and Nicki Thomas*

How we responded

Response of the professional community – *Paul Cockwell*

Response for and with patients – *Fiona Loud*

What we learnt and put in place

The experience of staff working in a highly affected inner city satellite unit of Tottenham Hale – *Tara Baptiste*

Caring for the carers: the impact of COVID on mental health of staff, support for staff as the clapping stops – *Janette Moran*

Supporting the effect on mental health in patients – *Dee Durham*

The experience of younger patients in the COVID19 using the Share: Survey results of the impact of COVID19 on younger people with kidney disease Young adult speaker – *Sarah and Thomas Alfree*

When your risks are high due to your ethnicity: patient experience of COVID19 – *Belinda Otas*

Planning for the future

After Shielding: mechanisms to support the most at risk – *Katie Vinen*

Planning for future: estates and unit design with pandemic in mind – *Rosie Donne*

How to manage general nephrology patients who require immunosuppression – *Marie Condon*

Panel discussion

18.30-18.45

Presidents' Closing Address

18.45-19.30

Exhibition,
posters and
networking



FOR FURTHER INFORMATION PLEASE CONTACT

UKKW c/o Executive Business Support Ltd
City Wharf, Davidson Road Lichfield
Staffordshire, WS14 9DZ
United Kingdom
Tel: 01543 442 192
E-mail: info@ukkw.org.uk
Website: www.ukkw.org.uk